Objective To study the drug resistance of neonatal sepsis caused by Klebsiella pneumoniae and provide evidence for drug treatment. Method Retrospectively analysis was conducted on the clinical data and antibiotic resistance of Klebsiella pneumoniae in 50 neonates with sepsis. Results The majority of the 50 cases were infected in hospital. There were 13 ESBLs strains in 50 Klebsiella pneumoniae strains (26%), and the others were negative ESBLs starins (74%). All the strains were multidrug-resistance to the β-lactam antibiotics and only sensitive to few antibiotics such as Imipenem and Amikacin. The sensitive rate was 100%. Conclusions The first selected antibiotic for the treatment of neonatal sepsis caused by Klebsiella pnemoniae was Imipenem or Amikacin.

Originating from Treatise on Cold Damage （ZHANG Zhongjing）， Wumeiwan is a representative prescription for pungent dispersing and bitter descending， upper clearing and warm purging， and combining cold and warm， which can be used to treat abdominal pain， enduring diarrhea， and syncope caused by cold and heat in complexity and asthenia in origin and sthenia in superficiality. Owing to the remarkable clinical efficacy， it is widely applied to the treatment of various internal injuries and external-contraction diseases. In recent years， the incidence of diseases of large intestine such as ulcerative colitis， Crohn's disease， and colorectal cancer has been on the rise， threatening the quality of life and health of patients. Major headway has been made in the clinical research on the treatment of the above diseases with Wumeiwan and on the mechanisms. However， no relevant summary is available， leading to the failure of further excavation and utilization of the value of this prescription in the treatment of the above diseases in time. Therefore， this paper reviews the theoretical basis， clinical research， and mechanism research of Wumeiwan and its modified formulas in the treatment of diseases of large intestine in recent years. The literature research suggests that Wumeiwan can effectively relieve clinical symptoms and reduce recurrence rate of large intestine diseases （including ulcerative colitis， Crohn's disease， diarrhea-predominant irritable bowel syndrome， colorectal cancer， chemotherapy-induced intestinal mucositis， and postoperative colorectal adenoma） with little adverse reactions. At the moment， the mechanisms of Wumeiwan against the above diseases are anti-inflammatory response， regulating immune function， repairing intestinal mucosal barrier， anti-tumor， regulating intestinal flora， anti-oxidative damage， analgesia， and inhibiting colonic epithelial cell apoptosis， but the specific molecular mechanism should be further explored. Through literature research， this paper comprehensively analyzes the theoretical basis， clinical research， and mechanisms of Wumeiwan in the treatment of diseases of large intestine， which is expected to serve as a reference for the further research on Wumeiwan in the prevention and treatment of diseases of large intestine and the mechanisms.